Kymera Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-74.4M | $76.0M |
| FY2020 | — | $283.9M | $31.0M |
| FY2021 | — | $459.6M | $48.0M |
| FY2022 | — | $490.2M | $68.4M |
| FY2023 | — | $395.0M | $110.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-74.4M | $76.0M |
| FY2020 | — | $283.9M | $31.0M |
| FY2021 | — | $459.6M | $48.0M |
| FY2022 | — | $490.2M | $68.4M |
| FY2023 | — | $395.0M | $110.0M |